Eli Lilly Eyes $2B Biotech Deal; UAE Seeks U.S. Financial Safety Net Amid Global Tensions
Summary
Eli Lilly and Co. (LLY) is reportedly in the final stages of a deal to acquire Kelonia Therapeutics, a clinical-stage biotech firm, for a sum exceeding $2
Description
Eli Lilly and Co. (LLY) is reportedly in the final stages of a deal to acquire Kelonia Therapeutics, a clinical-stage biotech firm, for a sum exceeding $2
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source